GlassScriptPhysician profile
Gregory B Pehling
NPI 1871595116
$869.49
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.58 · 2020: $32.27 · 2021: $94.93 · 2022: $237 · 2023: $117 · 2024: $152 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.39 | 2021-2023 | Jardiance |
| Gilead Sciences, INC. | $125.00 | 2025 | Epclusa |
| Lilly USA, LLC | $59.06 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Ultragenyx Pharmaceutical INC. | $38.92 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.75 | 2022 | |
| Corcept Therapeutics | $20.06 | 2025 | Korlym |
| Medtronic, INC. | $18.95 | 2022 | |
| Mylan Specialty L.P. | $18.86 | 2024 | Yupelri |
| Indivior INC. | $18.09 | 2024 | Sublocade |
| Abbvie INC. | $15.92 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.94 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.37 | 2024 | Gvoke Hypopen |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pehling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.